Idorsia Ltd 2022 Annual Report with Sustainability Disclosures
Company: Idorsia Ltd
Sector: Manufacturing
Country: Switzerland
Year: 2022
Type: Annual Report with Sustainability Disclosures
Pages: 116
The report describes Idorsia's 2022 transformation from a clinical-stage company into a fully fledged biopharmaceutical company, marked by the US launch of QUVIVIQ and Japan launch of PIVLAZ. It highlights a pipeline of more than 10 compounds and continued Phase 3 progress for aprocitantan, selatogrel, and cenerimod. The sustainability section presents a stakeholder-informed materiality assessment and, for the first time, references GRI and SASB standards.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.